Risk for Nephrogenic Systemic Fibrosis After Exposure to Newer Gadolinium Agents
- 23 June 2020
- journal article
- review article
- Published by American College of Physicians in Annals of Internal Medicine
- Vol. 173 (2), 110-119
- https://doi.org/10.7326/m20-0299
Abstract
This systematic review compares the risk for nephrogenic systemic fibrosis after exposure to newer versus older gadolinium-based contrast agents. Background: The risk for nephrogenic systemic fibrosis (NSF) after exposure to newer versus older gadolinium-based contrast agents (GBCAs) remains unclear. Purpose: To synthesize evidence about NSF...This publication has 64 references indexed in Scilit:
- Safety of meglumine gadoterate (Gd-DOTA)-enhanced MRI compared to unenhanced MRI in patients with chronic kidney disease (RESCUE study)European Radiology, 2012
- Nephrogenic systemic fibrosis: Clinicopathological definition and workup recommendationsJournal of the American Academy of Dermatology, 2011
- Low Risk for Nephrogenic Systemic Fibrosis in Nondialysis Patients Who Have Chronic Kidney Disease and Are Investigated with Gadolinium-Enhanced Magnetic Resonance ImagingClinical Journal of the American Society of Nephrology, 2010
- Retrospective assessment of prevalence of nephrogenic systemic fibrosis (NSF) after implementation of a new guideline for the use of gadobenate dimeglumine as a sole contrast agent for magnetic resonance examination in renally impaired patientsJournal of Magnetic Resonance Imaging, 2009
- Nephrogenic systemic fibrosis in liver disease: A systematic reviewJournal of Magnetic Resonance Imaging, 2009
- Incidence of nephrogenic systemic fibrosis at Chinese PLA General HospitalJournal of Magnetic Resonance Imaging, 2009
- Advances in Magnetic Resonance (2008)Investigative Radiology, 2008
- Gadolinium-based contrast agents and nephrogenic systemic fibrosis: a systematic review and meta-analysisNephrology Dialysis Transplantation, 2008
- Chronic inflammation and accelerated atherosclerosis as important cofactors in nephrogenic systemic fibrosis following intravenous gadolinium exposureClinical and Experimental Nephrology, 2008
- Risk for Nephrogenic Systemic Fibrosis with Gadoteridol (ProHance) in Patients Who Are on Long-Term HemodialysisClinical Journal of the American Society of Nephrology, 2008